Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Lymphoma, T-Cell, Peripheral 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sezary Syndrome 3Mycosis Fungoides 3Melanoma 3Lymphoma, Follicular 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡